Inhaled mannitol for the treatment of cystic fibrosis

References

• Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N. Engl. J. Med.335(3), 179–188 (1996).
   PubMed Web of Science ®Google Scholar
• Dodge JA, Morison S, Lewis PA et al. Incidence, population, and survival of cystic fibrosis in the UK, 1968–1995. Arch. Dis. Child.77(6), 493–496 (1997).
   PubMed Web of Science ®Google Scholar
• The Cystic Fibrosis Trust’s Clinical Standards and Accreditation Group. Standards for the clinical care of children and adults with cystic fibrosis in the UK 2001. CF Trust1–56 (2001).
   Google Scholar
• Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J. Intern. Med.261(1), 5–16 (2007).
   PubMed Web of Science ®Google Scholar
• Rowe SM, Miller S, Sorscher EJ. Cystic Fibrosis. N. Engl. J. Med.352(19), 1992–2001 (2005).
   PubMed Web of Science ®Google Scholar
• Donaldson SH, Boucher RC. Update on pathogenesis of cystic fibrosis lung disease. Curr. Opin. Pulm. Med.9(6), 486–491 (2003).
   PubMed Web of Science ®Google Scholar
• Frizzell RA, Pilewski JM. Finally, mice with CF lung disease. Nat. Med.10(5), 452–454 (2004).
   PubMed Web of Science ®Google Scholar
• Mall M, Grubb BR, Harkema JR, O’Neal WK, Boucher RC. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat. Med.10(5), 487–493 (2004).
   PubMed Web of Science ®Google Scholar
• Ratjen F, Doring G. Cystic fibrosis. Lancet361(9358), 681–689 (2003).
   PubMed Web of Science ®Google Scholar
• Cohen AB, Gold WM. Defense mechanisms of the lungs. Annu. Rev. Physiol.37(1), 325–350 (1975).
   PubMed Web of Science ®Google Scholar
• Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax51(2), 119–125 (1996).
   PubMed Web of Science ®Google Scholar
• Fuchs HJ, Borowitz DS, Christiansen DH et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl. J. Med.331(10), 637–642 (1994).
   PubMed Web of Science ®Google Scholar
• Quan JM, Tiddens HAWM, Sy JP et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J. Pediatr.139(6), 813–820 (2001).
   PubMed Web of Science ®Google Scholar
• Mccoy K, Hamilton S, Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest110(4), 889–895 (1996).
   PubMed Web of Science ®Google Scholar
• Konstan MW, Wagener JS, Pasta DJ et al.; for the Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Clinical use of dornase alfa is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr. Pulmonol.46(6), 545–553 (2011).
   PubMed Web of Science ®Google Scholar
• George PM, Banya W, Pareek N et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ342, d1008 (2011).
   PubMedGoogle Scholar
• Jones AP, Wallis C. Dornase alfa for cystic fibrosis. Cochrane Database Syst. Rev.17(3), CD001127 (2010).
   Google Scholar
• Heijerman H, Westerman E, Conway S, Touw D. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J. Cyst. Fibros.8(5), 295–315 (2009).
   PubMed Web of Science ®Google Scholar
• Scheffner AL, Medler EM, Jacobs LW, Sarett HP. The in vitro reduction in viscocity of human tracheobronchial secretions by acetylcysteine. Am. Rev. Respir. Dis.90, 721–729 (1964).
   PubMedGoogle Scholar
• Nash EF, Stephenson A, Atjen F, Tullis E. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst. Rev.21(1), CD007168 (2009).
   Google Scholar
• Elkins MR, Robinson M, Rose BR et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N. Engl. J. Med.354(3), 229–240 (2006).
   PubMed Web of Science ®Google Scholar
• Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst. Rev.2, CD001506 (2009).
   Google Scholar
• Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. Eur. Respir. J.22(6), 972–979 (2003).
   PubMed Web of Science ®Google Scholar
• Gustafsson PM, De Jong PA, Tiddens HAWM, Lindblad A. Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax63(2), 129–134 (2008).
   PubMed Web of Science ®Google Scholar
• Accurso FJ, Moss RB, Wilmott RW et al. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am. J. Respir. Crit. Care Med.183(5), 627–634 (2011).
   PubMedGoogle Scholar
• Joint Formulary Committee. British National Formulary 60. Joint Formulary Committee (Ed.). BMJ Group and Pharmaceutical Press, London, UK (2010).
   Google Scholar
• Anderson S, Charlton B, Weiler J et al. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. Respir. Res.10(1), 4 (2009).
   PubMed Web of Science ®Google Scholar
• Brannan J, Anderson S, Perry C et al. The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a Phase 3 comparison study with hypertonic (4.5%) saline. Respir. Res.6(1), 144 (2005).
   PubMed Web of Science ®Google Scholar
• Bilton D, Robinson P, Cooper P et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur. Respir. J.38(5), 1071–1080 (2011).
   PubMed Web of Science ®Google Scholar
• Investigator’s Brochure: bronchitol (inhaled dry powder mannitol for airway disease). Pharmaxis (10), section 4–6 (2010).
   Google Scholar
• Verdugo P. Goblet cells secretion and mucogenesis. Annu. Rev. Physiol.52(1), 157–176 (1990).
   PubMed Web of Science ®Google Scholar
• King M, Rubin B. Pharmacological approaches to discovery and development of new mucolytic agents. Adv. Drug Deliv. Rev.54(11), 1475–1490 (2002).
   PubMed Web of Science ®Google Scholar
• Wills PJ, Hall RL, Chan W, Cole PJ. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J. Clin. Invest.99(1), 9–13 (1997).
   PubMed Web of Science ®Google Scholar
• Brannan JD, Gulliksson M, Anderson SD, Chew N, Kumlin M. Evidence of mast cell activation and leukotriene release after mannitol inhalation. Eur. Respir. J.22(3), 491–496 (2003).
   PubMed Web of Science ®Google Scholar
• Robinson M, Daviskas E, Eberl S et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur. Respir. J.14(3), 678–685 (1999).
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Brannan JD, Chan HK, Eberl S, Bautovich G. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur. Respir. J.10(11), 2449–2454 (1997).
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson S, Eberl S, Chan HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am. J. Respir. Crit. Care Med.159(6), 1843–1848 (1999).
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Eberl S, Chan HK, Young IH. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest119(2), 414–421 (2001).
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Young IH. Effect of mannitol and repetitive coughing on the sputum properties in bronchiectasis. Respir. Med.104(3), 371–377 (2010).
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Eberl S, Young IH. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur. Respir. J.31(4), 765–772 (2008).
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Gomes K et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology10(1), 46–56 (2005).
   PubMed Web of Science ®Google Scholar
• Bilton D, Daviskas E, Jaques A, Anderson S, Charlton B. A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis. Am. J. Respir. Crit. Care Med.179, A3221 (2009).
   Google Scholar
• Jaques A, Daviskas E, Turton JA et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest133(6), 1388–1396 (2008).
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Jaques A, Charlton B. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest137(4), 861–868 (2010).
   PubMed Web of Science ®Google Scholar
• Minasian C, Wallis C, Metcalfe C, Bush A. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax65(1), 51–56 (2010).
   PubMed Web of Science ®Google Scholar
• Minasian C, Wallis C, Metcalfe C, Bush A. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis. Pediatr. Pulmonol.43(11), 1078–1084 (2008).
   PubMed Web of Science ®Google Scholar
• Teper A, Jaques A, Charlton B. Inhaled mannitol in patients with cystic fibrosis: a randomised open-label dose response trial. J. Cyst. Fibros.10(1), 1–8 (2011).
   PubMed Web of Science ®Google Scholar
• Joint FAO/WHO Expert Committee on Food Additives. 616. Mannitol. WHO Food Additives Series 21 (1986).
   Google Scholar
• Bartholdson SJ, Brown AR, Mewburn BR et al. Plant host and sugar alcohol induced exopolysaccharide biosynthesis in the Burkholderia cepacia complex. Microbiology154(8), 2513–2521 (2008).
   PubMed Web of Science ®Google Scholar